Project Grant R01HL179060
Award Date
6/3/25
Completion Date
4/30/29
Dollars Obligated
$502K
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Georgia, USA
Similar Awards
This $144,362 Project Grant awarded by the National Heart Lung and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) supports a research project focused on investigating the effectiveness and mechanisms of lymphaticovenous anastomoses (LVA) for treating lymphedema. The research integrates computational modeling with clinical LVA insights to gain a deeper understanding of lymphatic flow dynamics and adaptations in response to this surgical intervention. The project, led by...
Larix Bioscience LLC received a $245,728 Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837). The award supports the company's research and development of novel therapies for improving lymphatic dysfunction, a complication commonly associated with obesity and diabetes. Specifically, the grant funds the generation and preclinical evaluation of albumin and Fc fusion protein therapeutics targeting adrenomedullin...
This $647,359 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports the engineering of biomaterials with controlled biomolecule delivery for cardiovascular applications. The key products and services to be delivered include: Efficient and sustainable delivery of microRNA-145 from a novel biomaterial (PVA-CDI immobilized aminated fucoidan, or PCAF) to smooth muscle cells to induce a contractile...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $865,694 to The Children's Hospital Corporation (doing business as Boston Children's Hospital) to conduct research on controlling neuropilin-2 (NRP2) signaling to improve lymphatic function. The key objectives are to: 1) Alter NRP2 expression and ligand-dependent functions in the skin to sustain proper fluid drainage and...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $116,278 to the University of South Florida to investigate the role of the plasminogen activator (PA) pathway in lymphatic malformations. The key research activities include: Assessing the expression of key PA enzymes and utilizing in vitro zymography to evaluate matrix metalloproteinase (MMP) activation related to lymphatic valve defects...
This $580,863 Project Grant from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research Program (CFDA 93.837), supports research to develop improved cardiac regenerative therapies using engineered human cardiac organoids. The key products and services being delivered include: Optimizing the electrical properties and surface roughness of silicon nanowires incorporated into the cardiac organoids to enhance their interaction with human pluripotent stem...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $2,218,392.00 to Yale University to conduct research on the role of the lymphatic system in the pathogenesis of cerebral small vessel disease (CSVD) associated with chronic hypertension. The research aims to characterize the coupling between the glymphatic and lymphatic systems, determine how lymphatic drainage deficits contribute to...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $528,179 Project Grant (CFDA 93.837 Cardiovascular Diseases Research) to the University of Miami to investigate novel strategies for improving neovascularization and limb perfusion in peripheral arterial disease and critical limb ischemia. The research aims to determine if extracellular vesicles mediate a systemic effect that reprograms bone marrow-derived monocytes, and whether modulating the DHCR24 enzyme in myeloid cells can...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research federal grant program (CFDA 93.837), supports the development of a lesion-targeted nanotherapeutic to address vascular smooth muscle cell (VSMC) dysfunction and mitigate neointimal hyperplasia (NIH), which is a significant issue arising from vascular damage during interventions. The project aims to integrate in vitro transcribed CARMN RNA (a long non-coding RNA critical...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research Federal Grant Program (CFDA 93.837), aims to elucidate the role of the mechanosensitive ion channel Piezo1 in regulating lymphatic valve formation. The $808,121 award to the University of Southern California will support a 4-year research project to investigate how Piezo1 senses fluid flow and activates the Prox1 transcription factor, which is critical for lymphatic...